1 Start 2 Preview Answers 3 Complete Please complete the following pre-survey before attending the 2023 Annual meeting. First and Last Name * Email * According to the 2022 ACC Expert Consensus Decision Pathway on Non-Statin Therapies, which of the following is an appropriate LDL-C target in a woman with ASCVD, type 2 diabetes and hypertension? * ≥50% LDL-C reduction AND LDL-C <55 mg/dL ≥50% LDL-C reduction OR LDL-C <55 mg/dL ≥50% LDL-C reduction AND LDL-C <70 mg/dL ≥50% LDL-C reduction OR LDL-C <70 mg/dL ≥50% LDL-C reduction AND LDL-C <100 mg/dL ≥50% LDL-C reduction OR LDL-C <100 mg/dL Which of the following statements is TRUE about the CLEAR Outcomes trial with bempedoic acid? * It enrolled patients with existing ASCVD It enrolled patients at-risk for or with existing ASCVD Significant cardiovascular risk reduction was observed in the primary prevention cohort only It enrolled patients on high-intensity statin therapy True or False: according to the 2022 ACC consensus statement on non-statin therapies for LDL-C lowering, inclisiran and a PCSK9 inhibitor can be reasonably combined together in very high-risk patients that need further LDL-C lowering. * True False A 58-year-old woman with a recent myocardial infarction and stent placement to the LAD 6 months ago has been tried multiple statins and has severe myalgias with high intensity and moderate intensity statins. The patient is on a maximally tolerated dose of statin (pravastatin 20 mg daily). Ezetimibe 10 mg is then added and lipid profile reveals: total cholesterol = 261 mg/dL; triglycerides = 150 mg/dL ; HDL = 40 mg/dL; LDL-C = 175 mg/dL; LP(a) = 200 mg/dL. According to the 2022 ACC Expert Decision Pathway on non-statin therapies, which of the following options should you consider next to reduce the risk of future cardiovascular events? * Add a PCSK9 inhibitor Add inclisiran Add icosapent ethyl Add niacin Add bempedoic acid A 38-year-old patient with a recent ACS event, family history of ASCVD, has an elevated Lp(a) of 230 nmol/L, which was measured to better assess risk based on patient’s history. Patient is currently on high intensity statins for LDL-C lowering (current LDL-C = 115 mg/dL). Which of the following therapies would you recommend to also address elevated Lp(a) and further lower LDL-C? (select all that apply) Further optimize diet & lifestyle Substitute for another high-intensity statin Ezetimibe Bempedoic Acid PCSK9 inhibitors Inclisiran All of the above According to trials with PCSK9 inhibitors, which of the following is TRUE about the degree of benefit in reducing CV risk with these agents? * Benefits were relatively equal across enrolled patients Benefits were greater in patients with high-risk features Benefits occurred independently of baseline Lp(a) levels Benefits were greater in patients with lower baseline Lp(a) levels Please share 3-5 personal learning objectives and what you anticipate learning from the attending the 2023 CMHC Annual Meeting. * Leave this field blank
